<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200326046864N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-19</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>EMG-biofeedback in muscular dystrophy</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of effectiveness of strengthening exercises with and without EMG-biofeedback on function in  patients with muscular dystrophy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/46754</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: An independent researcher makes random allocation cards using computer-generated allocation table with stratification on sex and random block sizes of two and four within each stratum. He keeps the original random allocation sequences in an inaccessible third place and works with a copy. An unblinded clinical coordinator, who is not involved in testing or recruitment, will randomize subjects, Blinding description: Blinded study personnel will consist of the principal investigator, study coordinators, outcomes assessors, and the biostatistician. Unblinded study personnel will consist of the clinical coordinator and occupational therapists delivering the intervention. Participants will only be aware that they are participating in one of two potential rehabilitation programs and will be instructed to not discuss any details of their program with any blinded personnel.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Muscular dystrophy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: strengthening exercises using EMG-biofeedback.   EMG biofeedback is a method of retraining muscle by creating new feedback systems as a result of the conversion of myoelectrical signals in the muscle into visual and auditory signals. The program for intervention group utilizes the Loadsol® insoles (Novel.de, Munich, Germany) as real-time visual biofeedback during activity performance.The participants will do biofeedback assisted exercises for 6 weeks and 2 times a week with at least one day interval. Each session will take about 30-40 minutes.Exercises provided on the flexor, abductor and adductor muscles of the hip and knee  flexors and extensors. The participants will be assessed for retention of motor learning from the previous session on their current activities to determine if they are ready for intervention progression. The frequency of biofeedback will be faded to 50% using an intermittent biofeedback schedule along with random practice of the activities to promote retention of the improved movement pattern. The INTERVENTION group home exercise program will be the same as the CONTROL group home exercise program focusing on 10 strengthening and balance improving exercises. Intervention 2: Control group: strengthening exercises with occupational therapist supervision, Participants enrolled in the CONTROL program will focus on the same exercise protocol as the intervention program, though the treating occupational therapist will not provide any instructed feedback on movement patterns during their treatment beyond minimal cues for safety. Progression within activities in the CONTROL group will be based upon the participant's tolerance and safety in performing the activity. The CONTROL home exercise program will be the same as the intervention group but without use of biofeedback.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The findings of this study will be published as soon as possible.

When:
2022

To whom:
results will be available for journals readers
data will be available for reasonable requests for example systematic reviews

Conditions:
systematic review and meta analysis

Where to obtain:
Shariati Hospital, Tehran, Rehabilitation Department

How to obtain:
Through email: nasi_lam@yahoo.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nastaran Maghbouli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 25, Jalal Al-Ahmad Highway, North Kargar Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1418815516</zip>
        <telephone>+98 21 8490 2110</telephone>
        <email>nasi_lam@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nastaran Maghbouli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 25, Jalal Al-Ahmad Highway, North Kargar Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1418815516</zip>
        <telephone>+98 21 8490 2110</telephone>
        <email>nasi_lam@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Muscular dystrophy with proximal muscles involvement
Approved muscular dystrophy diagnosis by neurologist
Ability to walk 10 meters without help
To be volunteer for intervention</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Using drugs affecting muscular strength
Acute myositis
Orthopedic problems limiting patient movements
Other neurologic or systemic disease involving muscles
Skin lesion or infection at the site of electrode placements
History of symptomatic cardiomyopathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G71.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>G71.00 - Muscular dystrophy, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: strengthening exercises using EMG-biofeedback.   EMG biofeedback is a method of retraining muscle by creating new feedback systems as a result of the conversion of myoelectrical signals in the muscle into visual and auditory signals. The program for intervention group utilizes the Loadsol® insoles (Novel.de, Munich, Germany) as real-time visual biofeedback during activity performance.The participants will do biofeedback assisted exercises for 6 weeks and 2 times a week with at least one day interval. Each session will take about 30-40 minutes.Exercises provided on the flexor, abductor and adductor muscles of the hip and knee  flexors and extensors. The participants will be assessed for retention of motor learning from the previous session on their current activities to determine if they are ready for intervention progression. The frequency of biofeedback will be faded to 50% using an intermittent biofeedback schedule along with random practice of the activities to promote retention of the improved movement pattern. The INTERVENTION group home exercise program will be the same as the CONTROL group home exercise program focusing on 10 strengthening and balance improving exercises.</i_keyword>
      <i_keyword>Control group: strengthening exercises with occupational therapist supervision, Participants enrolled in the CONTROL program will focus on the same exercise protocol as the intervention program, though the treating occupational therapist will not provide any instructed feedback on movement patterns during their treatment beyond minimal cues for safety. Progression within activities in the CONTROL group will be based upon the participant's tolerance and safety in performing the activity. The CONTROL home exercise program will be the same as the intervention group but without use of biofeedback.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Muscle strength. Timepoint: before intervention, after 6 weeks intervention, 3 months post intervention. Method of measurement: dynamometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Motor Function. Timepoint: before, 6 weeks and 3 months post intervention. Method of measurement: The Motor Function Measure-32 scale.</sec_outcome>
      <sec_outcome>Fatigue severity. Timepoint: before, 6 weeks and 3 months post intervention. Method of measurement: Fatigue severity scale.</sec_outcome>
      <sec_outcome>Balance. Timepoint: before, 6 weeks and 3 months post intervention. Method of measurement: Berg Balance Scale.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: before, 6 weeks and 3 months post intervention. Method of measurement: SF-36 for quality of life evaluation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-27</approval_date>
        <contact_name>Ethics Committee of School of Medicine- Tehran University of Medical Sciences</contact_name>
        <contact_address>North Kargar Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
